Relapsed/Refractory Haematopoietic Malignancies (NCT04767308)
Sponsors:
Huazhong University of Science and Technology
Sponsors:
Huazhong University of Science and Technology
IND Enabling
Phase I
Phase II
Phase III
Relevant Interviews, Disease and Trial Updates and Stock-Markets News posted by CRISPR Medicine News.
Check also Companies to Follow in 2022 and CMN Markets for the latest stock and market trends.
Always stay updated with the free CMN Newsletter.
Shanghai IASO Biotechnology
Main focus: Gene editing for the treatment of cancer
Company stage: Clinical
Diseases: T- and B-cell malignancies
Genome editing tool: CRISPR-Cas9
Funding stage: Private
Location: Shanghai and Nanjing, China
Website: http://www.iasobio.com/
Pipeline: http://www.iasobio.com/proline.php
Shanghai IASO Biotechnology develops next generation allogeneic CAR-T cell therapies and uses CRISPR to make the CAR-T cells fratricide-resistent. The company is currently developing multiple pre-clinical programmes using CRISPR, to treat T- and B-cell malignancies.
